There are no announcements yet.
Diabetes mellitus often referred to as diabetes—is a condition in which the body either does not produce enough, or does not properly respond to, insulin, a hormone produced in the pancreas. Insulin enables cells to absorb glucose in order to turn it into energy. This causes glucose to accumulate in the blood (hyperglycemia), leading to various potential complications.
Many types of diabetes are recognized; The principal three are:
-Type 1: Results from the body's failure to produce insulin. It is estimated that 5-10% of Americans who are diagnosed with diabetes have type 1 diabetes. Presently, most persons with type 1 diabetes take insulin injections.
-Type 2: Results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with absolute insulin deficiency. Most Americans who are diagnosed with diabetes have type 2 diabetes.
-Gestational Diabetes: Pregnant women who have never had diabetes before but have high blood sugar (glucose) levels during pregnancy are said to have gestational diabetes. Gestational diabetes affects about 4% of all pregnant women. It may precede development of type 2 (or rarely type1) DM.
All forms of diabetes have been treatable since insulin became medically available in 1921, but a cure is difficult. Pancreas transplants have been tried with limited success in type 1 DM; gastric bypass surgery has been successful in many with morbid obesity and type 2 DM; and gestational diabetes usually resolves after delivery. Diabetes without proper treatments can cause many complications. Acute complications include hypoglycemia, diabetic ketoacidosis, or nonketotic hyperosmolar coma. Serious long-term complications include cardiovascular disease, chronic renal failure, retinal damage. Adequate treatment of diabetes is thus important, as well as blood pressure control and lifestyle factors such as smoking cessation and maintaining a healthy body weight.
At Hadassah Hebrew University Hospital in Jerusalem, researchers found that CBD (Cannabidiol) lowers the incidence of diabetes in young non-obese diabetes-prone (NOD) female mice. In their study they showed that administering CBD to 11-14 week old female NOD mice (either in a latent diabetes stage or with initial symptoms of diabetes) lessened the manifestations of the disease. In addition, “Diabetes was diagnosed in only 32% of the mice in the CBD-treated group, compared to 86% and 100% in the emulsifier-treated and untreated groups, respectively.”
If this type of data is found to be comparable in humans, a promising new form of treatment will emerge for this disease that afflicts at least 171 million people worldwide.
Recent GBXI News:
May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets
April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever...I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever important questions have been answered.
(1) Who's working on updating documentation? What's the % complete?
(2) Who owns and/or controls the CBIS Intellectual Property?
(3) is there another entity out there using the same name as Cannabis Science?
(4) WHERE IS BRINGING CBIS BACK PUBLIC AGAIN ON YOUR LIST OF PRIORITIES?
Can you please elaborate on these for us.
Show more
Hi Raymond,
Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:
On November 8, 2023; Capizate, Inc. (a 3rd party entity)...Hi Raymond,
Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:
On November 8, 2023; Capizate, Inc. (a 3rd party entity) reported a "Situation Analysis of GBXi" that it performed at GBXI's request; based upon 25 documents provided by GBXI; mostly pertaining to Cannabis Science, Inc. This report included listing: (a) Strengths, (b) Areas for Improvement, (c) CBIS Cancer Drug Valuation(s) [1 specifically], (d) as well as several additional items that supported it giving GBXI a Capitize Score = 623 out of a possible 1000. Getting the potential CBIS Drug Valuation(s) for just 1 drug @ 25Mil-29Mil is/was impressive; however the "Areas for Improvement" are significant:
Areas for improvement
---------------------
1. The business documents, agreements, term sheets, engagements are all dated in 2017-2018 and need to be updated.
2. Ownership and control of the intellectual property needs to be defined and confirmed.
3. A similar entity has active registration with California Secretary of State. The Company has a different address than on the Company website and also had a Statement of Info due to the California Secretary of State on 05/10/2023. Registered with the California Secretary of State as a Non-Profit Nonprofit Corporation - CA - Mutual Benefit. This will need to be defined.
Can you please let us know about the progress that has been made toward resolving these issues?? Even if you could reveal an estimated % complete for each line item that would be nice to see.
The report from November 8, 2023 says: "Your current phase in our process is phase three (Situation Analysis), four (Due Diligence Score), and five (Business Finance Documents – Specifically the analysis) the potential valuation" - out of a 7 phase process; (6) Capital Markets and (7) Post Capitalization. Even if you choose not to continue to use Capitize, Inc. any longer; these "Areas of Improvement" listed MUST BE addressed in order to bring CBIS back Trading again.
Thank you in advance of your response and Best Regards,
...Francis G. Cormier III
Show more
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
"We Own everything we speak about Owning,... Show more yesterday
Now that I'm past that NASTY Sickness phase we can... Show more yesterday